70岁及以上luminal A型早期乳腺癌保乳术后单模式内分泌治疗与放疗比较(EUROPA):3期非劣效随机试验的预设中期分析
EUROPA是一项在意大利17个中心和斯洛文尼亚1个中心开展的非劣效3期随机试验,纳入70岁及以上、组织学确诊I期luminal A型乳腺癌且已行保乳手术的患者,1:1随机接受单模式内分泌治疗或放疗。预设中期分析纳入放疗组104例、内分泌治疗组103例,中位随访23.9个月;24个月时全球健康状况评分较基线的校正平均变化放疗组为-3.40,内分泌治疗组为-9.79,校正组间差异6.39 favoring放疗。
要点
- 24个月全球健康状况评分较基线的校正平均变化:放疗组-3.40,内分泌治疗组-9.79,组间差异6.39 favoring放疗。
- 治疗相关不良事件放疗组65/97例(67%),内分泌治疗组76/89例(85%)。
- 3-4级不良事件最常见为关节痛:内分泌治疗组6/89例(7%)vs 放疗组0/97例。
核心结论
- 24个月时内分泌治疗较放疗与更大的全球健康状况评分下降相关。
- 作者认为这些中期结果提示放疗可能更好保留老年低风险早期乳腺癌患者的生活质量。
- 作者指出仍需疾病控制结局的进一步数据和最终入组完成才能得出确定结论。
研究设计与样本
- 非劣效3期随机试验,在意大利17个中心和斯洛文尼亚1个中心共18个学术医院开展。
- 纳入70岁及以上、组织学确诊I期luminal A型乳腺癌、已行保乳手术且ECOG体能状态为0或1的女性。
- 1:1随机分配接受单模式内分泌治疗或放疗,按G8筛查工具的健康状态和年龄分层,分配隐藏且未设盲。
- 内分泌治疗为每日口服芳香化酶抑制剂或他莫昔芬,计划总疗程5-10年,由临床酌情决定;放疗为全乳或部分乳腺照射,分5-15次。
- 共同主要终点为24个月时EORTC QLQ-C30全球健康状况量表评估的健康相关生活质量变化和5年同侧乳腺肿瘤复发率(本文未报告后者)。
主要发现
- 患者以白人为主(204/207,99%);中位年龄放疗组75.0岁(IQR 73.0-80.0),内分泌治疗组74.0岁(72.0-80.0)。
- 完成24个月健康相关生活质量评估者:放疗组86例,内分泌治疗组75例。
- 基线全球健康状况平均评分放疗组71.9(SD 19.1),内分泌治疗组75.5(19.3)。
- 24个月时经年龄和G8评分校正的全球健康状况较基线平均变化:放疗组-3.40(95%CI -7.82至1.03;p=0.13),内分泌治疗组-9.79(-14.45至-5.13;p<0.0001),校正平均差异6.39(0.14至12.65;p=0.045)favoring放疗。
- 治疗相关不良事件放疗组65/97例(67%),内分泌治疗组76/89例(85%)。
局限性
- 作者指出仍需疾病控制结局的进一步数据和最终入组完成才能得出确定结论。
- 本文报告的5年同侧乳腺肿瘤复发率未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal therapy following breast-conserving surgery in older adults with low-risk, early-stage breast cancer remains uncertain. The EUROPA trial aims to compare the effects of radiotherapy and endocrine therapy as single-modality treatments on health-related quality of life (HRQOL) and ipsilateral breast tumour recurrence (IBTR) outcomes in this population. METHODS: This non-inferiority, phase 3, randomised study was conducted at 18 academic hospitals across Italy (17 centres) and Slovenia (one centre). Eligible patients were women aged 70 years or older with histologically confirmed, stage I, luminal A-like breast cancer, who had undergone breast-conserving surgery and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to receive single-modality endocrine therapy or radiotherapy. Endocrine therapy consisted of daily oral aromatase inhibitors or tamoxifen, for a total planned duration of 5-10 years as per clinical discretion, while radiotherapy was administered as either whole breast or partial breast irradiation, delivered in 5-15 fractions. Randomisation was stratified by health status according to the Geriatric 8 (G8) screening tool and by age, with allocation concealed and no blinding. The co-primary endpoints were the change in HRQOL, assessed by the global health status (GHS) scale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core module at 24 months, and 5-year IBTR rates (not reported here). This preplanned interim analysis was performed once at least 152 patients completed the 24-month GHS HRQOL assessment. The safety population comprised patients who received the study intervention at least once after randomisation. The study is registered with ClinicalTrials.gov, NCT04134598, and is ongoing and actively recruiting. FINDINGS: Between March 4, 2021, and June 14, 2024, 731 women were randomly assigned to receive radiotherapy (n=365) or endocrine therapy (n=366). This analysis included 104 patients in the radiotherapy group and 103 in the endocrine therapy group, with a median follow-up of 23·9 months (IQR 22·9-24·2). Patients were predominantly White (204 [99%] of 207) and the median age was 75·0 years (IQR 73·0-80·0) in the radiotherapy group and 74·0 years (72·0-80·0) in the endocrine therapy group. 86 patients in the radiotherapy group and 75 in the endocrine therapy group completed the 24-month HRQOL assessment. The mean baseline GHS score was 71·9 (SD 19·1) in the radiotherapy group and 75·5 (19·3) in the endocrine therapy group. At 24 months, the age-adjusted, G8 score-adjusted mean change from baseline in GHS was -3·40 (95% CI -7·82 to 1·03; p=0·13) in the radiotherapy group and -9·79 (-14·45 to -5·13; p<0·0001) in the endocrine therapy group, with an adjusted mean difference of 6·39 (0·14 to 12·65; p=0·045) favouring radiotherapy. Treatment-related adverse events were less frequent in the radiotherapy group (65 [67%] of 97 patients) compared with the endocrine therapy group (76 [85%] of 89). The most common grade 3-4 adverse events were arthralgia (six [7%] of 89 in the endocrine therapy group vs 0 of 97 in the radiotherapy group), pelvic organ prolapse (three [3%] vs 0), fatigue, hot flashes, myalgia, bone pain, and fractures (two [2%] vs 0 for each). Serious adverse events were reported in 15 (15%) patients in the radiotherapy group and 13 (15%) in the endocrine therapy group. There were no treatment-related deaths in either group. INTERPRETATION: Endocrine therapy was associated with a greater reduction in HRQOL, as measured by GHS, compared with radiotherapy at 24 months. While these interim results suggest radiotherapy might better preserve HRQOL in older women with low-risk early breast cancer, further data on disease control outcomes and final patient accrual are needed to draw definitive conclusions. FUNDING: Fondazione Radioterapia Oncologica.
引用
- Meattini I, De Santis MC, Visani L, et al. Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial. Lancet Oncol. 2024. PMID: 39675376. doi:10.1016/S1470-2045(24)00661-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。